Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $114.58M
• Dividend Yield: N/A
• Average Volume (3M): 123.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: -99.07%
• EPS Growth: -10347.56%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.84
• Shares Outstanding: 24,071,750
• 10 Day Avg. Volume: 185,671
• 30 Day Avg. Volume: 123,923
• PEG Ratio: -0.03
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -0.44
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: 19.48
• Enterprise Value/Gross Profit: -20.23
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $45.00
• Price Target Upside: 895.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $4.50 ▼(-0.44% Downside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenues and substantial losses. Technical analysis also indicates a bearish trend, with the stock trading below key moving averages. Valuation metrics further highlight the company's challenges, with a negative P/E ratio and no dividend yield. The promising trial results are a positive development but do not significantly offset the financial and technical concerns.

Positive Factors

Promising Clinical Trial Results

The ELIMINATE-B trial results demonstrate potential for a breakthrough in hepatitis B treatment, enhancing the company's competitive position in gene editing.

Strategic Partnerships

Strategic partnerships leverage shared resources and expertise, potentially accelerating drug development and expanding market reach.

Capital Raise for R&D

The capital raise will fund ongoing R&D, supporting innovation and long-term growth in developing advanced therapeutic solutions.

Negative Factors

Declining Revenue

Significant revenue decline indicates challenges in product sales and market penetration, impacting financial stability and growth prospects.

Negative Cash Flow

Persistent negative cash flow suggests difficulty in sustaining operations without external funding, posing risks to long-term viability.

Substantial Losses

Substantial losses reflect inefficiencies and high operational costs, challenging the company's ability to achieve profitability and financial health.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc. (DTIL) is a biotechnology company that specializes in gene editing and genetic medicine. The company is primarily focused on developing advanced therapeutic solutions using its proprietary ARCUS technology, which is designed to create precision genetic modifications in various organisms, including human cells. Precision BioSciences operates in sectors such as gene therapy, cell therapy, and agricultural biotechnology, and is working towards addressing significant unmet medical needs in areas like oncology and genetic disorders.

How the Company Makes Money

Precision BioSciences generates revenue through a combination of product sales, research collaborations, and licensing agreements. The company partners with pharmaceutical and biotechnology firms to develop therapies using its ARCUS gene editing technology, earning revenue through milestone payments and royalties from successful product developments. Additionally, Precision BioSciences may receive funding from government grants and research contracts aimed at advancing its innovative therapies. Significant partnerships with other biotech companies enhance its revenue potential by allowing shared resources and expertise in drug development.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences is facing significant financial difficulties, characterized by declining revenues, substantial losses, and negative cash flows. While there are some improvements in leverage, the company's profitability and cash generation remain major concerns.

Income Statement

Precision BioSciences has faced significant challenges in its income statement, with a negative revenue growth rate of -44.65% in the TTM period, indicating a sharp decline in sales. The company also reported negative margins across the board, with a net profit margin of -119.77% and an EBIT margin of -87.0%, highlighting substantial losses relative to revenue. These factors suggest a struggling financial performance with limited profitability.

Balance Sheet

The balance sheet shows a mixed picture. The debt-to-equity ratio improved to 0.09 in the TTM period, indicating lower leverage compared to previous years. However, the return on equity remains deeply negative at -213.79%, reflecting ongoing losses. The equity ratio stands at 17.79%, suggesting a moderate level of equity financing relative to total assets.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating cash flow and free cash flow. The free cash flow growth rate improved by 14.43% in the TTM period, but the operating cash flow to net income ratio of -4.89 indicates that cash outflows significantly exceed net income. The free cash flow to net income ratio of 1.00 suggests that free cash flow is closely aligned with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	698.00K	68.70M	48.73M	25.10M	115.53M	24.29M
Gross Profit	-672.00K	68.70M	48.73M	25.10M	115.53M	24.29M
EBITDA	-79.30M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
Net Income	-83.60M	7.17M	-61.32M	-111.64M	-30.60M	-109.01M
Balance Sheet
Total Assets	93.51M	136.39M	159.78M	238.17M	211.50M	150.16M
Cash, Cash Equivalents and Short-Term Investments	44.87M	86.31M	116.68M	189.58M	143.66M	89.80M
Total Debt	29.13M	30.05M	31.27M	24.96M	9.11M	10.52M
Total Liabilities	76.88M	80.00M	140.92M	177.74M	120.33M	105.73M
Stockholders Equity	16.63M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow
Free Cash Flow	-73.69M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
Operating Cash Flow	-73.28M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
Investing Cash Flow	-406.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
Financing Cash Flow	23.57M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 4.52 is below the 20-day moving average (MA) of 4.94, below the 50-day MA of 5.91, and below the 200-day MA of 5.16, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 35.34 is Neutral, neither overbought nor oversold. The STOCH value of 20.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	66 Neutral	$696.38M	9.28	66.76%	―	-10.26%	144.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLUE	51 Neutral	―	―	―	―	127.51%	56.94%
IMA	41 Neutral	$73.09M	-0.76	-33.05%	―	-100.00%	45.48%
DTIL	41 Neutral	$114.58M	-0.54	-205.16%	―	-99.07%	-10347.56%
ACRV	36 Underperform	$72.89M	-1.06	-50.23%	―	―	21.17%
ACET	27 Underperform	$72.08M	-0.37	-71.73%	―	―	25.89%

Precision BioSciences Corporate Events

Precision BioSciences Announces $70M Stock Offering

On November 10, 2025, Precision BioSciences, Inc. announced an underwriting agreement with Guggenheim Securities, LLC for the sale of 10,815,000 shares of common stock and accompanying warrants, expecting to raise approximately $70 million. The proceeds will be used for research and development, working capital, and other corporate purposes, with the offering’s closing anticipated on November 12, 2025, subject to customary conditions.

Precision BioSciences Unveils Promising ELIMINATE-B Trial Results

On November 10, 2025, Precision BioSciences announced significant findings from its ELIMINATE-B clinical trial, which evaluates the PBGENE-HBV therapy for hepatitis B. The trial demonstrated consistent antiviral activity and durable reductions in hepatitis B surface antigen across various dose levels, with no dose-limiting toxicities observed. The promising results, including direct evidence of HBV DNA editing, suggest a potential path to a cure, positioning the company favorably in the gene editing landscape and offering hope for stakeholders seeking effective hepatitis B treatments.